Literature DB >> 18630499

Invasion front-specific overexpression of tissue inhibitor of metalloproteinase-1 in liver metastases from colorectal cancer.

C Kahlert1, O R Bandapalli, P Schirmacher, J Weitz, K Brand.   

Abstract

BACKGROUND: Matrix metalloproteinases (MMPs) and their inhibitors, the tissue inhibitors of metalloproteinases (TIMPs), have been implicated in invasion and metastasis. The distribution of MMPs and TIMPs in the invasion front of liver metastases from colorectal cancer were investigated in order to understand their potential role in invasiveness.
MATERIALS AND METHODS: Freshly frozen material of colorectal metastases of the liver was microdissected into four separate compartments, namely pure liver, liver invasion, tumour invasion and pure tumour. RNA was isolated and analyzed on Affymetrix microarrays. Expression of TIMP-1 was confirmed by quantitative polymerase chain reaction in 10 colorectal liver metastases. Cellular localisation of TIMP-1 was examined by immunohistochemistry.
RESULTS: Affymetrix microarray data revealed that several MMP and TIMP genes including MMP-2, -3, -7, -9, -11, -12, -14, -15, -16, -19 and -24, and TIMP-1, -2 and -3 were generally up-regulated in both invasion front compartments. Among these genes, TIMP-1 showed the highest expression. The qPCR results indicated an average 15-fold upregulation of TIMP-1 in the liver invasive front and an average 13-fold up-regulation in the tumor invasive front, each compared to normal liver tissue. Immunohistochemistry revealed expression of TIMP-1 in tumour epithelia as well as in host tissue cells, including fibroblastic cells.
CONCLUSION: Our data indicate that tumour invasion in colorectal liver metastasis is associated with increased TIMP-1 RNA and protein levels in both tumour and host cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18630499

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

Review 1.  Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression.

Authors:  Kyle J Isaacson; M Martin Jensen; Nithya B Subrahmanyam; Hamidreza Ghandehari
Journal:  J Control Release       Date:  2017-01-31       Impact factor: 9.776

2.  Immune cells in primary and metastatic gastrointestinal stromal tumors (GIST).

Authors:  Silke Cameron; Marieke Gieselmann; Martina Blaschke; Giuliano Ramadori; Laszlo Füzesi
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

3.  Investigating the Radioresistant Properties of Lung Cancer Stem Cells in the Context of the Tumor Microenvironment.

Authors:  Ryan Chan; Pallavi Sethi; Amar Jyoti; Ronald McGarry; Meenakshi Upreti
Journal:  Radiat Res       Date:  2016-02-02       Impact factor: 2.841

4.  Differences in plasma TIMP-1 levels between healthy people and patients with rectal cancer stage II or III.

Authors:  Irena Oblak; Franc Anderluh; Vaneja Velenik; Barbara Mozina; Janja Ocvirk; Eva Ciric; Natasa Hrovatic Podvrsnik
Journal:  Radiol Oncol       Date:  2011-08-26       Impact factor: 2.991

5.  The correlation between the levels of tissue inhibitor of metalloproteinases 1 in plasma and tumour response and survival after preoperative radiochemotherapy in patients with rectal cancer.

Authors:  Irena Oblak; Vaneja Velenik; Franc Anderluh; Barbara Mozina; Janja Ocvirk
Journal:  Radiol Oncol       Date:  2013-05-21       Impact factor: 2.991

6.  Extravesicular TIMP-1 is a non-invasive independent prognostic marker and potential therapeutic target in colorectal liver metastases.

Authors:  Venkatesh Sadananda Rao; Qianyu Gu; Sandra Tzschentke; Kuailu Lin; Nicole Ganig; May-Linn Thepkaysone; Fang Cheng Wong; Heike Polster; Lena Seifert; Adrian M Seifert; Nathalie Buck; Carina Riediger; Jonas Weiße; Tony Gutschner; Susanne Michen; Achim Temme; Martin Schneider; Franziska Baenke; Jürgen Weitz; Christoph Kahlert
Journal:  Oncogene       Date:  2022-02-09       Impact factor: 8.756

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.